Citius Pharmaceuticals Inc

CTXR

Add to Watchlist

0.700USD

-0.020-2.72%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Citius Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

181 / 382

Overall Ranking

328 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Citius Pharmaceuticals Inc Highlights

StrengthsRisks

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Fairly Valued

The company’s latest PE is -0.33, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.71M shares, decreasing 40.13% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+733.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Citius Pharmaceuticals Inc is 6.89, ranking 167 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.89

Change

0



Financials

5.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.99

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Citius Pharmaceuticals Inc is 7.02, ranking 176 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.33, which is -98.59% below the recent high of -0.00 and -2290.02% above the recent low of -7.79.

Score

Industry at a Glance

Previous score

7.02

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 181/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Citius Pharmaceuticals Inc is 7.00, ranking 312 out of 382 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Citius Pharmaceuticals Inc is 4.79, ranking 335 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.96 and the support level at 0.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.82

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Citius Pharmaceuticals Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.32%, representing a quarter-over-quarter decrease of 27.96%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Heights Capital Management, Inc.

799.93K

-45.21%

Mazur (Leonard L)

410.21K

--

Geode Capital Management, L.L.C.

127.53K

+6.48%

XTX Markets LLC

107.12K

+572.77%

Two Sigma Investments, LP

89.42K

+310.11%

Holubiak (Myron Z)

79.69K

--

BlackRock Institutional Trust Company, N.A.

69.85K

--

Asset Advisory Group Inc

59.01K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Citius Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Citius Pharmaceuticals Inc

CTXR

5.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment